SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

its a Meme token and beta to Troll The "Lenny face  is a text-based emoticon, ( ͡° ͜ʖ ͡°), used to convey a range of emotions, particularly mischief, sexual innuendo, or a hidden meaning. It's often employed in online discussions to add a playful or suggestive tone to a message, or sometimes even to spam threads, according to Wikipedia. The symbol is visually interpreted as a face with two eyes (small circles), a nose (squiggly line), and a mouth (curved line).

Lenny

LENNY is trending as community members rally around the meme coin, emphasizing its strong community and cultural relevance within the Solana ecosystem. Discussions highlight the coin's resilience during market dips and potential for future growth, with community members encouraging others to join the 'cult' following.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending amid speculation surrounding a potential SpaceX IPO and renewed interest in space infrastructure. Community discussions highlight the possibility of sector re-ratings and potential contract awards, while also weighing valuation concerns. Some investors are taking profits while others see long-term potential.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending as cannabis stocks react to speculation around potential federal policy changes, including the possibility of the Trump administration reclassifying marijuana, which could ease restrictions and provide tax benefits to cannabis companies. Community members are actively discussing potential entry points, trading strategies around options, and the possible impact on specific companies within the sector. Some caution against hype, noting previous false starts, while others express optimism for substantial gains if rescheduling occurs.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token ($YEE) is trending with community members highlighting its explosive momentum and resilience, particularly within the Ethereum ecosystem. Bullish sentiment is fueled by increased volume across multiple exchanges, and holders believe $YEE is carving out a strong position as the next big meme token.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation and rumors surrounding potential marijuana rescheduling, with community members citing reports of a possible executive order from President Trump as soon as Monday. Discussions include the impact of rescheduling on the company, potential price targets, and the possibility of a short squeeze. The community's bullish sentiment is fueled by the potential for eased regulations and increased investment in the cannabis sector.

Trulieve Cannabis Corp. engages in the provision of medical cannabis products and services. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Quincy, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis

Trulieve Cannabis ($TCNNF) is trending amid speculation around potential cannabis rescheduling and its impact on the industry, with community members discussing the possibility of gains and strategic positioning. Some investors believe that rescheduling is near, while others express skepticism due to past disappointments. The potential for federal policy changes and the stock's perceived undervaluation are key talking points.

Etsy, Inc. engages in the operation of an online marketplace. It offers handmade products such as shoes, clothing, bags, and accessories. It operates through the following segments: Etsy, Reverb, and Depop. The company was founded in 2005 and is headquartered in New York, NY.

Etsy Inc

Etsy is trending as traders discuss potential holiday season tailwinds and marketplace expansion. Bullish sentiment is fueled by actionable trade alerts and technical analysis pointing to constructive intraday structure. Community members are also weighing factors like the stock's valuation and potential impact from AI initiatives.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

SNAP is trending as investors debate its future, with discussions around its AI partnership with Perplexity, potential for growth, and the impact of regulations like Australia's proposed social media ban for those under 16. Bullish arguments include undervaluation and potential for a turnaround, while bearish concerns focus on profitability, leadership, and the company's ability to compete.

The 401jk (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and also the 401k. The 401k total holdings are valued at around $12 trillion USD and it is the most popular retirement savings plan in the US. As time passes forevermore true retirement, or as we like to call it real freedom will only become much harder and harder for people to attain.  Through meme fueled laser focus and cyperphunk ideology the 401jK meme retirement fund token and community aim to point out the absurdities of how rigged our current system is, and how only insiders and those with power are starting the benefit from the increased centralization of cryptocurrency.........while also aiming to flip the $12 trillion USD 401k system to achieve freedom before our backs and knees are breaking.

401jK

401jK is trending as community members rally around its mission to redefine retirement and challenge traditional financial systems. Bullish sentiment is fueled by the project's strong community, new exchange listings, and the belief that it addresses widespread frustration with conventional 401(k) plans. The community is actively promoting the token's vision of financial freedom through memes and content creation.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is trending as the community discusses its volatile price action and potential connection to the broader AI sector following recent market fluctuations. Some traders are pointing to data center growth as a bullish catalyst, while others are wary of overvaluation and potential market manipulation. Discussions also include potential support levels and debate about whether the stock is a long-term hold.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Illustration showing chimeric antigen receptor (CAR) T cells (blue and green) being used to treat non-small cell lung cancer (NSCLC). | Representative image: Getty Images

Why Did Aethlon Medical Stock Tumble Over 12% Today?

Aethlon Medical's stock drew investor attention after the company announced a private placement and warrant inducement deal. 

Equity

Aethlon Medical's stock drew investor attention after the company announced a private placement and warrant inducement deal. 


Rising stock market chart on a trading board background.

Entero Therapeutics Stock Jumps After Company Rebrands As GridAI Technologies Corp.

The name change follows the company’s acquisition of GRID AI Corp in October.

<ul class="summary-bullets"><li>The company expects gross proceeds of about $60 million from the offering, which it intends to use for general corporate purposes.</li><li>Pasithea expects the offering to close on or about December 1.</li></ul><p>Pasithea Therapeutics Corp. (KTTA) on Friday announced the pricing of a public offering of 80 million shares of the company’s common stock at $0.75 per share.</p><p>KTTA shares traded 43% higher on Friday morning at the time of writing.</p><h2 class="st-heading-2">Offering Proceeds And Purpose</h2><p>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/28/3196323/0/en/Pasithea-Therapeutics-Announces-Pricing-of-60-Million-Public-Offering-of-Common-Stock.html">expects</a> gross proceeds of about $60 million from the offering, which it intends to use for general corporate purposes such as ongoing research and pre-clinical studies, clinical trials, the development of new biological and pharmaceutical technologies, and investing in or acquiring companies that are synergistic with or complementary to the company’s technologies, among others.</p><p>The offer price represents a 29% discount to the stock’s Wednesday closing price.</p><p>The company said that it expects the offering, led by investors including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron Capital Management, to close on or about December 1. The offering will extend its cash runway through at least the first half of 2028, it added. &nbsp;</p><p>Earlier this month, the company was awarded a Hoffman ALS Clinical Trial Award grant worth about $1 million to study its lead drug candidate, PAS-004, in Amyotrophic lateral sclerosis (ALS) patients. ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, where patients eventually lose the ability to breathe.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KTTA">KTTA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.</p><p>A Stocktwits user opined that the stock will erode its gains to hit $0.75 level.</p><p><stembedurl>https://stocktwits.com/GABBYGIRL/message/637652497</stembedurl></p><p>KTTA stock is down by 52% this year.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/china-byd-recalls-nearly-89000-evs/cL5aGIxRELP">China’s BYD Recalls Nearly 89,000 EVs – Regulator Cites Battery Output Concerns</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Why Did KTTA Stock Soar A Whopping 43% Today?

The company announced the pricing of a public offering of 80 million shares of its common stock and said that the offering will extend its cash runway through at least the first half of 2028.

<ul class="summary-bullets"><li>The company has now proposed an early-stage clinical trial to evaluate the cell therapy.</li><li>Lunai is also advancing additional studies and expanding the clinical reach of its DCCT platform through collaborations with investigators in non-small cell lung cancer and prostate cancer.</li><li>The company is also preparing for formal licensing negotiations and pursuing activities ahead of the commencement of human clinical trials in early 2026.</li></ul><p>&nbsp;</p><p>Shares of Lunai Bioworks (LNAI) jumped 26% in the pre-market session on Tuesday after the company announced that it has secured its first letter of intent (LOI) to license its next-generation immune cell therapy.</p><p>"We are seeing accelerating validation from both researchers and industry partners," <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/lunai-bioworks-secures-first-licensing-loi-following-landmark-breakthrough-showing-complete-tumor-regression-in-humanized-cancer-models-302624947.html">said</a> CEO David Weinstein. He added that the early licensing activity reflects growing confidence in the platform's potential to unlock scalable treatments.</p><h2 class="st-heading-2">Data For Cell Therapy</h2><p>The cell therapy, Dendritic Cell Combination Therapy (DCCT), achieved complete regression of both primary and metastatic pancreatic tumors with no recurrence in humanized preclinical models.</p><p>The company has now proposed an early-stage clinical trial to evaluate the cell therapy, manufactured from healthy donor cells and stored ready-to-use, across several high-risk tumors, including pancreatic cancer, which has a poor survival rate.</p><h2 class="st-heading-2">Plans Ahead</h2><p>Lunai is also advancing additional studies and expanding the clinical reach of its DCCT platform through collaborations with investigators in non-small cell lung cancer and prostate cancer.</p><p>Additionally, it is preparing for formal licensing negotiations and pursuing activities ahead of the commencement of human clinical trials in early 2026.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around LNAI jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/LNAI">LNAI stock</a> is down by 85% this year and by about 75% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-experimental-glp-1-drug-shows-weight-loss-blood-sugar-level-reduction-in-study/cL52hCvREXo">Novo Nordisk’s Experimental GLP-1 Drug Shows Weight Loss, Blood Sugar Levels Reduction In Study</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

 In this photo illustration, the Lunai Bioworks logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

LNAI Stock Soars Pre-Market After Immune Cell Therapy Gains Licensee Interest 

The cell therapy, Dendritic Cell Combination Therapy (DCCT), achieved complete regression of both primary and metastatic pancreatic tumors with no recurrence in humanized preclinical models.

<ul class="summary-bullets"><li>If the proposed bidding process is approved, interested parties can submit binding offers to acquire Clearside’s assets in whole or in part.</li><li>CEO George Lasezkay said that the company has “attractive assets,” including its SCS Injection Platform.&nbsp;</li><li>The company has also filed several motions to enable normal operations during the process, it said.&nbsp;<br>&nbsp;</li></ul><p>Clearside Biomedical, Inc. (CLSD) said on Monday that it has filed a voluntary petition for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware.</p><p>Shares of the company traded nearly 69% lower at the time of writing.</p><h2 class="st-heading-2">What Does The Company Intend?</h2><p>The biopharmaceutical company is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/24/3193383/0/en/Clearside-Biomedical-to-Pursue-Strategic-Sale-of-its-Business-Through-Voluntary-Chapter-11-Process.html">seeking</a> authorization to pursue an auction and sale process. If the proposed bidding process is approved, interested parties can submit binding offers to acquire Clearside’s assets in whole or in part.</p><p>"Our Board of Directors and management team have thoroughly assessed all of our strategic options and believe that this Chapter 11 structured process represents the best possible option for Clearside and its stakeholders,” said CEO George Lasezkay.</p><p>Lasezkay also added that the company has “attractive assets,” including its SCS Injection Platform, which is a proven in-office, repeatable, non-surgical procedure for the targeted delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.</p><p>The company’s CLS-AX clinical development program is also up for sale. CLS-AX is being developed for the treatment of serious back-of-the-eye diseases, including neovascular age-related macular degeneration (wet AMD) and diabetic retinopathy.</p><p>The company has also filed several motions to enable normal operations during the process, it said.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around CLSD jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume stayed at ‘high’ levels.</p><figure class="image"><img style="aspect-ratio:587/60;" src="data:image/png;base64,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" width="587" height="60" alt="CLSD’s Sentiment Meter and Message Volume as of 11:21 a.m. ET on Nov. 24, 2025 | Source: Stocktwits"><figcaption>CLSD’s Sentiment Meter and Message Volume as of 11:21 a.m. ET on Nov. 24, 2025 | Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/CLSD">CLSD stock</a> is down by 94% this year and by about 95% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/oscar-health-stock-soars-on-reports-of-two-year-obamacare-subsidy-extension/cL5bB5mREQ7">Oscar Health Stock Soars On Reports Of Two-Year Obamacare Subsidy Extension</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

 In this photo illustration, the Clearside Biomedical logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CLSD Stock Plummets After Company Files For Bankruptcy Protection

The biopharmaceutical company is seeking authorization to pursue an auction and sale process.

In this photo illustration, the Tempest Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction

The transaction is expected to close in early 2026, provided it receives all required approvals. 

<ul class="summary-bullets"><li>The January meeting is intended to discuss the clinical trial design, patient population, and a potential approval route for Buntanetap in PDD.&nbsp;</li><li>According to Annovis, PDD affects approximately 30% of Parkinson’s patients.&nbsp;</li><li>The company also said that its late-stage Alzheimer’s Disease study is ongoing with full regulatory alignment.</li></ul><p>Annovis Bio, Inc. (ANVS) on Tuesday said the U.S. Food and Drug Administration (FDA) has scheduled a January 2026 meeting to discuss the company's pathway to developing Buntanetap for the treatment of Parkinson's disease dementia.</p><p>Parkinson's disease dementia (PDD) is a type of dementia that occurs in people who already have Parkinson's disease, characterized by cognitive decline, such as memory problems and slowed thinking, along with the movement issues of PD. According to Annovis, PDD affects approximately 30% of Parkinson’s patients.</p><h2 class="st-heading-2">What Will Be Discussed At The Meeting?</h2><p>The meeting in January is aimed at discussing the clinical trial design, patient population, and a potential approval route for Buntanetap in PDD, the company said. According to Annovis executive Cheng Fang, PDD is a natural extension of the company’s Alzheimer's and Parkinson's programs, wherein the company generated data demonstrating meaningful cognitive improvement with Buntanetap.</p><p>"The scheduled January meeting marks a key milestone for our pipeline, underscoring buntanetap's potential across multiple neurodegenerative indications and the strength of our scientific approach."<br>Maria Maccecchini, CEO, Annovis</p><h2 class="st-heading-2">Alzheimer’s Trial Progress</h2><p>The Malvern, Pennsylvania-headquartered company also said that its late-stage Alzheimer’s Disease study is ongoing with full regulatory alignment on study design, endpoints, and patient population.</p><p>The study is set to support applications for the drug in symptomatic treatment and disease-modifying treatment with Buntanetap.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p><a href="https://stocktwits.com/symbol/ANVS">ANVS shares</a> traded 16% higher at the time of writing. On Stocktwits, retail sentiment around ANVS remained in the ‘extremely bullish’ territory, while message volume remained at ‘extremely high’ levels.</p><figure class="image"><img style="aspect-ratio:624/61;" src="data:image/png;base64,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" width="624" height="61" alt="ANVS's Sentiment Meter and Message Volume as of 12:06 p.m. ET on Nov. 18, 2025 | Source: Stocktwits"><figcaption>ANVS's Sentiment Meter and Message Volume as of 12:06 p.m. ET on Nov. 18, 2025 | Source: Stocktwits</figcaption></figure><p>ANVS stock fell 31% this year and by 49% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/waymo-announces-robotaxi-launch-in-five-more-cities/cLPV4fyRE7M">Waymo Announces Robotaxi Launch In Five More Cities</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Global stock market chart and trading board - stock photo

Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia

The meeting with the FDA is scheduled for January 2026. 

<ul class="summary-bullets"><li>The strategic review comes after Neuphoria discontinued advancing its lead drug candidate called BNC210 for the treatment of social anxiety disorder in October.</li><li>Strategic alternatives under consideration may include, but are not limited to, mergers, acquisitions, partnerships, joint ventures, licensing arrangements, or other strategic transactions, the company said.</li><li>The company said it will carefully evaluate and consider Lynx1 Master Fund’s indication of interest in connection with its review of strategic alternatives.</li></ul><p><br>Neuphoria Therapeutics Inc. (NEUP) initiated a review of strategic alternatives, including potential acquisitions, on Tuesday to advance its pipeline programs and maximize shareholder value.</p><p>NEUP shares traded 4% higher in the pre-market session at the time of writing.</p><h2 class="st-heading-2">Strategic Alternatives Under Consideration</h2><p>Strategic alternatives under consideration may include, but are not limited to, mergers, acquisitions, partnerships, joint ventures, licensing arrangements, or other strategic transactions, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.neuphoriatx.com/news-releases/news-release-details/neuphoria-announces-initiation-strategic-review-maximize">said.</a></p><p>The company added that it does not have a defined timeline for exploring strategic alternatives. Further, it is not confirmed that the process will result in a transaction.</p><p>The strategic review comes after Neuphoria discontinued advancing its lead drug candidate called BNC210 for the treatment of social anxiety disorder in October after a late-stage trial missed its primary and secondary endpoints. Neuphoria then also said it will assess new development paths for BNC210 as a treatment for post-traumatic stress disorder (PTSD).</p><h2 class="st-heading-2">Lynx1 Master Fund Expresses Interest</h2><p>Neuphoria on Tuesday also added that it received an unsolicited non-binding indication of interest from Lynx1 Master Fund LP earlier this week to acquire all of the outstanding shares of Neuphoria that it does not already own for $5.20 per share in cash. The company said it will carefully evaluate and consider this indication of interest in connection with its review of strategic alternatives.</p><p>Lynx1 Master Fund LP also expressed intent to nominate certain individuals to stand for election to Neuphoria’s Board of Directors at the company’s 2025 Annual Meeting of Stockholders, the company said. Neuphoria’s Board of Directors will now review the proposed director nominees. The annual meeting is scheduled for December 12.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NEUP">NEUP stock</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.</p><figure class="image"><img style="aspect-ratio:623/62;" src="data:image/png;base64,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" width="623" height="62" alt="NEUP's Sentiment Meter and Message Volume as of 8:28 a.m. ET on Nov. 11, 2025 | Source: Stocktwits"><figcaption>NEUP's Sentiment Meter and Message Volume as of 8:28 a.m. ET on Nov. 11, 2025 | Source: Stocktwits</figcaption></figure><p>NEUP stock is up by 43% this year and by 11% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/poet-technologies-and-quantum-computing-team-up-to-boost-ai-data-speeds/cLPdoHVREPl">POET Technologies And Quantum Computing Team Up To Boost AI Data Speeds</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

NEUP Shares Rise Pre-Market As It Explores Strategic Alternatives, Including Potential Acquisition

Neuphoria also added that it received an unsolicited non-binding indication of interest from Lynx1 Master Fund LP earlier this week to acquire all of the outstanding shares of Neuphoria that it does not already own for $5.20 per share in cash. 

<p>Shares of Caribou Biosciences, Inc. (CRBU) jumped 52% in the pre-market session on Monday after the company announced positive data from early-stage trials of two of its CAR-T cell therapies.</p><p>While one of the therapies was evaluated for the treatment of multiple myeloma, a blood cancer of plasma cells, the other was assessed in B-cell non-Hodgkin lymphoma (NHL), a cancer that originates in B lymphocytes, a type of white blood cell that fights infection.</p><h2 class="st-heading-2">Study In Multiple Myeloma</h2><p>The company said that the first clinical data for its CB-011 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3179047/0/en/Caribou-Biosciences-Announces-Positive-Data-from-CaMMouflage-Phase-1-Trial-of-CB-011-in-Multiple-Myeloma.html">highlights</a> its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.</p><p>The company now expects to advance the program into the dose expansion phase by the end of the year. In the dose escalation portion of the trial, CB-011 had a manageable safety profile across all dose levels, the company noted. The portion of the trial evaluated the safety and efficacy of CB-011 in 48 patients at multiple dose levels and following two different chemotherapy treatments.</p><h2 class="st-heading-2">Study In B-cell non-Hodgkin lymphoma</h2><p>Meanwhile, data from an early-stage trial of vispacabtagene regedleucel (Vispa-cel) demonstrated the efficacy and durability of the cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3179104/0/en/Caribou-Biosciences-Announces-Positive-Data-from-ANTLER-Phase-1-Trial-Demonstrating-Efficacy-and-Durability-of-Vispa-cel-CB-010-an-Allogeneic-CAR-T-Cell-Therapy-on-Par-with-Autolog.html">said</a>. Vispa-cel was generally well-tolerated, allowing for administration in the outpatient setting, the company added.</p><p>“We believe that with these results, Caribou has achieved what the field has long sought — strong evidence that an allogeneic CAR-T cell therapy can be on par with the efficacy and durability of autologous treatments and broaden access with a safety profile that allows for outpatient use,” said CEO Rachel Haurwitz.</p><p>Allogeneic CAR-T cell therapy is a type of "off-the-shelf" cancer treatment that uses T-cells from a healthy donor, rather than the patient's own cells, allowing immediate availability. Autologous therapy, however, uses a patient's own cells or tissues, which are collected, processed outside the body, and then reintroduced to the same individual.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CRBU">CRBU stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.</p><p>CRBU stock is up 52% this year and approximately 3% over the past 12 months.&nbsp;</p><p>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-sales-in-us-rise-1.6-percent-in-october/cL2NX8OR3CR">Ford Sales In US Rise 1.6% In October On Continued Truck Demand</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For  Cancer Treatments

The company announced positive data from trials of CB-011 and Vispa-cel in relapsed or refractory multiple myeloma and B-cell non-Hodgkin lymphoma, respectively. 

<ul class="summary-bullets"><li>The agency has requested more information regarding an excipient in the formulation of SER-252, the company said.&nbsp;</li><li>The company said that it intends to work with the FDA to address its concerns.<br>&nbsp;</li></ul><p>Shares of Serina Therapeutics (SER) slumped 7% in the pre-market session on Monday after the company announced that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on its application to initiate clinical trials for its advanced Parkinson’s disease therapy candidate.</p><p>The agency has requested more information regarding an excipient in the formulation of SER-252, the company said. An excipient is a substance, other than the active pharmaceutical ingredient (API), that is deliberately included in a drug formulation.</p><p>Serina<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3178999/0/en/Serina-Therapeutics-Provides-Regulatory-Update-on-SER-252-Program.html"> noted</a> that the agency’s feedback does not relate to its active drug substance or its proposed action mechanism.</p><h2 class="st-heading-2">What Are The Steps Forward?</h2><p>The company said that it intends to work with the FDA to address its concerns. Serina expects to receive the FDA’s formal clinical-hold letter within 30 days and provide an update once it has aligned with the agency on the next steps.</p><blockquote><p>“We appreciate the FDA’s engagement and constructive feedback. We will provide the additional information requested promptly as we continue to move forward in the registrational trial for SER-252.”&nbsp;<br>-Steve Ledger, CEO, Serina Therapeutics.</p></blockquote><p>Board Member of Serina and Co-Founder and Executive Chairman of Juvenescence, Greg Bailey, has pledged to continue supporting the company financially and strategically in the initiation of clinical trials for SER-252. The registrational study of SER-252 is designed to evaluate the safety, tolerability, and pharmacokinetics of subcutaneous SER-252 compared to placebo, and will be conducted across sites in the U.S. and Australia.</p><p>“This update does not change our conviction in Serina’s long-term potential or our belief in SER-252’s ability to meaningfully improve the lives of patients with advanced Parkinson’s disease,” he added.</p><h2 class="st-heading-2"><br>How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SER">SER stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘high’ levels.</p><p>SER stock is down 0.2% this year and approximately 22% over the past 12 months.&nbsp;</p><p>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/vertiv-bets-1-billion-on-ai-infrastructure-buys-liquid-cooling-firm-purge-rite/cL2NPfzR3za">Vertiv Bets $1 Billion On AI Infrastructure, Buys Liquid-Cooling Firm PurgeRite</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Serina Therapeutics Stock Slumps Pre-Market After FDA Places Hold On Application To Initiate Clinical Trials For Experimental Therapy

Serina noted that the agency’s feedback does not relate to its active drug substance or its proposed action mechanism.

Current Price	$213.72
Prev Close	$217.28
Open	$217.43
Dividend Yield	N/A
50-Day Moving Average	$209.50
Beta	N/A
Avg. Volume	380,699.58
PE Ratio	N/A

52-Week High	$217.58
52-Week Low	$146.68
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

VXF
Vanguard Extended Market ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VXF News

VXFVanguard Extended Market ETF